TARA
Protara Therapeutics Inc.
$3.67
+$0.48(+15.05%)
41
Overall
--
Value
41
Tech
--
Quality
Market Cap
$118.45M
Volume
3.09M
52W Range
$1.60 - $10.48
Target Price
$22.17
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $-3.4M | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $-3.4M | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $-3.4M | -- | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $21.4M | $7.8M | $34.4M | $47.5M | $37.5M | $43.6M | $49.2M | ||
| Research & Development | $11.8M | $3.9M | $12.0M | $21.1M | $16.8M | $25.0M | $31.7M | ||
| Research Expense | $11.8M | $3.9M | $12.0M | $21.1M | $16.8M | $25.0M | $31.7M | ||
| Selling, General & Administrative | $9.5M | $4.0M | $22.5M | $26.4M | $20.7M | $18.6M | $17.4M | ||
| General & Administrative Expenses | $9.5M | $4.0M | $22.5M | $26.4M | $20.7M | $18.6M | $17.4M | ||
| Salaries & Wages | -- | $-424.0K | $9.7M | $10.4M | $6.7M | $6.1M | $4.1M | ||
| Depreciation & Amortization | $-115.0K | $-16.0K | $103.0K | $117.0K | $248.0K | $341.0K | $332.0K | ||
| Depreciation & Amortization | $-115.0K | $-16.0K | $103.0K | $117.0K | $248.0K | $341.0K | $332.0K | ||
| Amortization | -- | -- | $-150.0K | $29.5M | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | $308.0K | $2.5M | $1.4M | $1.4M | $1.4M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-21.4M | $-7.8M | $-34.4M | $-47.5M | $-67.1M | $-43.6M | $-49.2M | ||
| EBITDA | $-20.7M | $-7.8M | $-33.8M | $-45.4M | $-64.6M | $-53.3M | $-63.7M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | -- | $34.0K | $1.7M | $1.1M | -- | -- | ||
| Intinc | -- | -- | $500.0K | $237.0K | $1.1M | $3.2M | $4.2M | ||
| Net Non-Operating Interest Income/Expense | $436.0K | $262.0K | $466.0K | $237.0K | $-1.1M | $3.2M | $4.2M | ||
| Gain on Sale of Securities | -- | -- | $500.0K | $237.0K | $17.0K | -- | -- | ||
| Other Income/Expense | $-207.0K | -- | $-500.0K | $1.5M | $-29.5M | $-3.2M | $-387.0K | ||
| Other Special Charges | $207.0K | -- | $9.8M | $-1.7M | $-1.1M | $3.2M | $387.0K | ||
| SPECIAL ITEMS | |||||||||
| Restructring And Mn A Income | -- | $22.8M | $33.8M | $33.8M | -- | -- | -- | ||
| Special Income Charges | -- | $-22.8M | $-33.8M | $-33.8M | $-29.5M | $12.0K | $36.0K | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $29.5M | -- | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-20.7M | $-7.8M | $-33.9M | $-45.5M | $-64.8M | $-54.2M | $-64.4M | ||
| Pre-Tax Income | $-20.7M | $-7.8M | $-34.0M | $-47.3M | $-66.0M | $-40.4M | $-44.6M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-430.0K | $2.5M | $-8.7M | $-8.9M | $-9.0M | $-13.8M | $-19.8M | ||
| NET INCOME | |||||||||
| Net Income | $-20.7M | $-7.8M | $-34.0M | $-47.3M | $-66.0M | $-40.4M | $-44.6M | ||
| Net Income (Continuing Operations) | $-20.7M | $-7.8M | $-34.0M | $-47.3M | $-66.0M | $-40.4M | $-44.6M | ||
| Net Income (Discontinued Operations) | $-20.7M | $-7.8M | $-34.0M | $-47.3M | $-66.0M | $-40.4M | $-44.6M | ||
| Net Income (Common Stockholders) | $-20.7M | $-7.8M | $-34.0M | $-47.3M | $-66.0M | $-40.4M | $-44.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-64.4M | ||
| TOTALS | |||||||||
| Total Expenses | $21.4M | $7.8M | $34.4M | $47.5M | $37.5M | $43.6M | $49.2M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $452.6K | $497.3K | $7.2M | $11.2M | -- | $11.3M | $20.6M | ||
| Average Shares Outstanding (Diluted) | $452.6K | $497.3K | $7.2M | -- | $11.3M | $11.3M | $20.6M | ||
| Shares Outstanding | $481.1K | $5.8M | $11.2M | $11.3M | $11.3M | $38.6M | $38.6M | ||
| Basic EPS | $-46 | $-30.15 | $-4.7 | $-4.21 | $-5.86 | $-3.57 | $-2.17 | ||
| Basic EPS (Continuing Operations) | $-46 | $-30.15 | $-4.7 | $-4.21 | $-5.86 | $-3.57 | $-2.17 | ||
| Diluted EPS | $-46 | $-30.15 | $-4.7 | $-4.21 | $-5.86 | $-3.57 | $-2.17 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-5.86 | $-3.57 | $-2.17 | ||
| OTHER METRICS | |||||||||
| Excise Taxes | $3.4M | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $9.5M | $4.0M | $22.5M | $26.4M | $20.7M | $18.6M | $17.4M | ||
| Rent And Landing Fees | -- | -- | -- | -- | -- | $-1.1M | $-1.1M | ||
| Othspecchg | -- | -- | -- | -- | -- | $-12.0K | $-36.0K | ||
| Restruct | -- | $22.8M | $33.8M | $33.8M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TARA | $3.67 | +15.0% | 3.09M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Protara Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW